883535-89-5

Usage

Uses

Used in Pharmaceutical Industry:
2-(2-METHYL-1H-INDOL-1-YL)ETHANAMINE is used as a therapeutic agent for the treatment of mood disorders such as depression and anxiety. Its potential role in mood regulation and modulation of physiological processes makes it a promising candidate for pharmaceutical applications.
Used in Sleep Aid Industry:
2-(2-METHYL-1H-INDOL-1-YL)ETHANAMINE is used as a sleep aid for the treatment of sleep disorders. Its potential role in the regulation of circadian rhythms and sleep cycle control makes it a valuable component in sleep aid formulations.
Used in Research:
2-(2-METHYL-1H-INDOL-1-YL)ETHANAMINE is used as a research compound for studying the effects of psychoactive substances on mood, sleep, and physiological processes. Its presence in trace amounts in the human brain and its potential therapeutic effects make it an important subject for scientific investigation.
Note: Due to its psychoactive effects and potential for abuse, 2-(2-METHYL-1H-INDOL-1-YL)ETHANAMINE has been classified as a controlled substance in some jurisdictions. Its use and distribution are subject to regulatory restrictions and guidelines.

InChI:InChI=1/C11H14N2/c1-9-8-10-4-2-3-5-11(10)13(9)7-6-12/h2-5,8H,6-7,12H2,1H3

Upstream product

• 95-20-5 2-methyl-1H-indole 
• 870-24-6 2-chloroethanamine hydrochloride 
• 104894-21-5 2-(2-methyl-1H-indol-1-yl)acetonitrile 

Downstream Products

• 1415604-20-4 (E)-3-(4-methoxyphenyl)-N-(2-(2-methyl-1H-indol-1-yl)ethyl)acrylamide 
• 1415602-43-5 N-(2-(2-methyl-1H-indol-1-yl)ethyl)-3-(3,4,5-trimethoxyphenyl)propanamide 
• 1609030-81-0 3-amino-N-(2-(2-methyl-1H-indol-1-yl)ethyl)-3-(3,4,5-trimethoxyphenyl)propanamide 
• 1609030-91-2 (E)-3-(4-(2-hydroxyethoxy)phenyl)-N-(2-(2-methyl-1H-indol-1-yl)ethyl)acrylamide 
• 1609030-93-4 (E)-3-(4-(3-hydroxypropoxy)phenyl)-N-(2-(2-methyl-1H-indol-1-yl)ethyl)acrylamide 
• 1609030-95-6 (E)-3-(4-(2-hydroxyethoxy)-3,5-dimethoxyphenyl)-N-(2-(2-methyl-1H-indol-1-yl)ethyl)acrylamide 
• 1609030-98-9 2-(4-fluorophenyl)-N-(2-(2-methyl-1H-indol-1-yl)ethyl)cyclopropane-1-carboxamide 
• 1609031-01-7 (E)-3-(4-(3-(dimethylamino)propoxy)phenyl)-N-(2-(2-methyl-1H-indol-1-yl)ethyl)acrylamide 
• 1609031-02-8 (E)-3-(4-(2-(dimethylamino)ethoxy)phenyl)-N-(2-(2-methyl-1H-indol-1-yl)ethyl)acrylamide 
• 1609031-00-6 (E)-3-(4-(2-(dimethylamino)ethoxy)-3,5-dimethoxyphenyl)-N-(2-(2-methyl-1H-indol-1-yl)ethyl)acrylamide 
• 1416881-62-3 (E)-3-(3,5-dimethoxyphenyl)-N-(2-(2-methyl-1H-indol-1-yl)ethyl)acrylamide 
• 1416881-61-2 (E)-3-(4-fluoro-3,5-dimethylphenyl)-N-(2-(2-methyl-1H-indol-1-yl)ethyl)acrylamide 
• 689264-90-2 3,4-dimethoxy-N-(2-(2-methyl-1H-indol-1-yl)ethyl)benzamide 
• 689264-34-4 4-methoxy-N-(2-(2-methyl-1H-indol-1-yl)ethyl)benzamide 

Relevant academic research and scientific papers

N-SUBSTITUTED INDOLE DERIVATIVES

The present invention relates to derivatives of formula (I) Formula (I) wherein R1, and R 2 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals,

N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS

The present invention relates to derivativesof formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation,

PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO

The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, neuroinflamation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.

Lead optimization studies of cinnamic amide EP2 antagonists

Prostanoid receptor EP2 can play a proinflammatory role, exacerbating disease pathology in a variety of central nervous system and peripheral diseases. A highly selective EP2 antagonist could be useful as a drug to mitigate the inflammatory consequences of EP2 activation. We recently identified a cinnamic amide class of EP2 antagonists. The lead compound in this class (5d) displays anti-inflammatory and neuroprotective actions. However, this compound exhibited moderate selectivity to EP2 over the DP1 prostanoid receptor (～10-fold) and low aqueous solubility. We now report compounds that display up to 180-fold selectivity against DP1 and up to 9-fold higher aqueous solubility than our previous lead. The newly developed compounds also display higher selectivity against EP4 and IP receptors and a comparable plasma pharmacokinetics. Thus, these compounds are useful for proof of concept studies in a variety of models where EP2 activation is playing a deleterious role.